Unicycive Therapeutics (UNCY) traded down -7.97 % during a 24 hours period ending at 10:12 PM Central Europe on Tuesday 27th. One Unicycive Therapeutics stock can currently be bought for about USD 3.61 on popular exchanges. Current supply of Unicycive Therapeutics stocks is 27.8 mn. Unicycive Therapeutics has a current market capitalization of USD 106.1 mn and approximately USD 4.7 mn worth of Unicycive Therapeutics was traded on exchanges in the last 24 hours. Since last month end, Unicycive Therapeutics has traded -22.84 % down. Simple moving average of last 200 days is at USD 6.15. The highest price of past 52 weeks was recorded at USD 8.74 on 05/14/2026. 52 weeks low was at USD 3.35 on 10/16/2026.

Here is how related stocks have performed in the past 24 hours:

  • Ascent Industries (ACNT) traded down -2.94 % and now trades at USD 13.68. Current market capitalisation for Ascent Industries is USD 125.6 mn. Ascent Industries Co. announced that it will hold its third‑quarter 2026 earnings conference call on November 4, 2026, at 5:00 p.m. Eastern time. The call will follow a press release that will detail the company’s financial results for the quarter ending September 30, 2026. Management will host the discussion and field questions during a Q&A segment. Participants can register for the webcast or dial in using the provided links, and the recording will be available for replay for one year on the company’s investor relations website. The announcement reaffirmed Ascent’s focus on developing, producing, and distributing performance‑driven chemical solutions.

  • Kvh Industries (KVHI) traded up 3.07 % and now trades at USD 7.47. Kvh Industries has a market capitalisation of USD 123.4 mn.

  • Skyai (SKYA) traded flat 0 % and now trades at USD 2.91. Skyai has a market capitalisation of USD 124.2 mn.

  • Spruce Biosciences (SPRB) traded down -2.57 % and now trades at USD 45.65. Spruce Biosciences has a market capitalisation of USD 126.5 mn.

  • Macrogenics (MGNX) traded down -2.67 % and now trades at USD 2.44. Macrogenics has a market capitalisation of USD 126.8 mn. MacroGenics Inc. reported interim results from its Phase 2 LINNET study of lorigerlimab, a bispecific antibody targeting PD‑1 and CTLA‑4, in patients with advanced clear cell gynecologic cancer. The study, presented at the ESMO Congress, showed that about a quarter of evaluable patients experienced tumour shrinkage, with a further portion maintaining disease control. The therapeutic effect was observed in patients who had previously received one or more lines of treatment, and all responses remained ongoing at the data cutoff. Safety data indicated that most adverse events were manageable, with a minority of patients discontinuing treatment due to side effects. MacroGenics is enrolling additional participants at a lower dose and expects to share updated outcomes in the first half of 2027.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc. is a biotechnology company based in Los Altos, United States, that specializes in the development of two novel therapies for treating hyperphosphatemia in patients with chronic kidney disease and acute kidney injury.